Clinical Trial Update: Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravesical Nanoxel®M for efficacy and safety in BCG-refractory non-muscle invasive bladder cancer; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Nanoxel M (docetaxel)

Snippet

Sponsor: Samyang Biopharmaceuticals Corporation | Conditions: Non Muscle Invasive Bladder Cancer | Phase 3 | Status: TERMINATED